VIP in Neurological Diseases: More Than A Neuropeptide

Author(s): Maria Morell, Luciana Souza-Moreira, Elena Gonzalez-Rey.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 12 , Issue 4 , 2012

Become EABM
Become Reviewer

Abstract:

A hallmark in most neurological disorders is a massive neuronal cell death, in which uncontrolled immune response is usually involved, leading to neurodegeneration. The vasoactive intestinal peptide (VIP) is a pleiotropic peptide that combines neuroprotective and immunomodulatory actions. Alterations on VIP/VIP receptors in patients with neurodenegerative diseases, together with its involvement in the development of embryonic nervous tissue, and findings found in VIP-deficient mutant mice, have showed the relevance of this endogenous peptide in normal physiology and in pathologic states of the central nervous system (CNS). In this review, we will summarize the role of VIP in normal CNS and in neurological disorders. The studies carried out with this peptide have demonstrated its therapeutic effect and render it as an attractive candidate to be considered in several neurological disorders linked to neuroinflammation or abnormal neural development.

Keywords: Neuroimmunology, neuroinflammatory diseases, neurological disorders, neuropeptides, VIP, TISSUE EXPRESSION, NORMAL ADULT BRAIN PHYSIOLOGY, neuroendocrine–immune communication, Neuroimmune interactions, multiple sclerosis (MS), Parkinson’s and Alzheimer´s disease (PD) and AD, NEURODEVELOPMENTAL DISORDERS.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 4
Year: 2012
Page: [323 - 332]
Pages: 10
DOI: 10.2174/187153012803832549
Price: $65

Article Metrics

PDF: 27